Rabeprazole Sodium

CAS Number: 117976-90-6

Molecular Formula: C18H20N3NaO3S

Proton Pump Inhibitor (PPI)Acid-Suppressing AgentGrade: IPTherapeutic Category: Anti-ulcer

About Rabeprazole Sodium

Rabeprazole Sodium or (Rabeprazole na) a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H⁺/K⁺-ATPase enzyme system at the secretory surface of gastric parietal cells, an action that leads to a reduction in gastric acidity, providing relief from acid-related disorders. Rabeprazole t...

Synonyms

1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
Aciphex
dexrabeprazole
E 3810

View all

Rabeprazole Sodium Specifications

CAS Number

117976-90-6

Molecular Formula

C18H20N3NaO3S

IUPAC Name

sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide

Canonical SMILES

CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]

InChI Key

KRCQSTCYZUOBHN-UHFFFAOYSA-N

InChI

1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1

CAS Number

117976-90-6

Molecular Formula

C18H20N3NaO3S

IUPAC Name

sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide

Canonical SMILES

CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]

InChI Key

KRCQSTCYZUOBHN-UHFFFAOYSA-N

InChI

1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1

Appearance

White to off-white crystalline powder

Melting Point

140–141°C (decomposes)

Solubility in Water

Soluble (10 mg/mL) Stability Hygroscopic; stable under recommended storage conditions

Storage Conditions

Store at -20°C in a tightly sealed container

Hazard Classification

Acute Toxicity (Oral) Category 4; Hazardous to the aquatic environment, chronic hazard, Category 4

Signal Word

Warning

Hazard Statements

H302: Harmful if swallowed H413: May cause long lasting harmful effects to aquatic life

Precautionary Statements

P264: Wash hands thoroughly after handling P270: Do not eat, drink, or smoke when using this product P273: Avoid release to the environment P301+P312: IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell P501: Dispose of contents/container in accordance with local/regional/national/international regulations

Treatment of (GERD)

Used to alleviate symptoms and promote healing in patients with GERD by reducing gastric acid secretion.

Management of (PUD)

Aids in the healing of duodenal and gastric ulcers by inhibiting acid production.

Eradication of Helicobacter pylori Infection

Employed as part of combination therapy to eliminate H. pylori, reducing the risk of ulcer recurrence.

Treatment of Zollinger-Ellison Syndrome

Manages pathological hypersecretory conditions by suppressing excessive gastric acid production.

Formulation in Delayed-Release Tablets

Commonly formulated in enteric-coated tablets to ensure stability and targeted release in the intestine.

Mechanism of Action

Irreversibly binds to and inhibits the H⁺/K⁺-ATPase enzyme system, leading to prolonged suppression of gastric acid secretion.

Bioavailability

Approximately 52% following oral administration.

Protein Binding

Approximately 96.3%.

Metabolism

Extensively metabolized in the liver via CYP2C19 and CYP3A4 isoenzymes.

Elimination Half-Life

Approximately 1 hour.

Excretion

Primarily excreted in urine as metabolites. Pharmacopoeial Standards: Complies with USP, EP, and BP specifications.

Storage Conditions

Store at -20°C in a tightly sealed container, protected from light and moisture.

Packaging

Available in various quantities suitable for pharmaceutical manufacturing needs.

COA

Download

1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
Aciphex
dexrabeprazole
E 3810

Rabeprazole Sodium FAQs

Minimum Order Quantity

25 kg (evaluation) · 1 MT (commercial)

Lead Time

3 – 5 weeks estimated

Delivery Terms

FOB*

Packaging

20 L pails, 200 L HDPE drums, 1000 L IBC

US Availability

US Facility Inventory

Documentation

US SDS · COA · TDS · Specification sheet

US Regulatory & Quality Information

TSCA status*

US SDS / HazCom*

GHS classification*

ISO 9001:2015 site*

DOT shipping classification*

FDA status*

EPA status*

California Prop 65*

Reliable US supply chain

Regulatory compliance

On-time delivery

Technical expert support

Explore Pharmaceutical Portfolio

CAS No : 5743-26-0

Calcium acetate monohydrate

Category : Pharmaceutical Actives & Precursors

Sub-Category : Active Pharmaceutical Ingredients (APIs)

Description : Calcium acetate monohydrate (CAS No: 5743-26-0) occupies a critical position in the global specialit...

View Product

CAS No : 14168-73-1

Magnesium Sulphate Monohydrate

Category : Pharmaceutical Actives & Precursors, Inorganic Chemicals

Sub-Category : Active Pharmaceutical Ingredients (APIs), Inorganic Salts

Description : We supply high-efficiency magnesium sulphate monohydrate (CAS No: 14168-73-1) archieved across inter...

View Product

CAS No : 122-04-3

P-Nitrobenzoyl Chloride

Category : Pharmaceutical Actives & Precursors

Sub-Category : Intermediates & Precursors

Description : P-Nitrobenzoyl Chloride (CAS 122-04-3) is a critical building block in the API intermediates market,...

View Product

CAS No : 35271-74-0

Category : Pharmaceutical Actives & Precursors

Sub-Category : Active Pharmaceutical Ingredients (APIs)

Description : 3-(4-Chlorophenyl)glutaric acid (CAS 35271-74-0) is a pivotal building block in the API intermediate...

View Product

Company

Resources

Partner with us

Rabeprazole Sodium